We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current CLPBY market cap is 25.98B. The company's latest EPS is DKK 2.4034 and P/E is 48.76.
| Year End 30 September 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | |
| Total Revenue | 18.54B | 19.43B | 22.58B | 24.5B | 27.03B |
| Operating Income | 5.85B | 6.16B | 6.44B | 6.77B | 7.32B |
| Net Income | 4.2B | 4.83B | 4.71B | 4.78B | 5.05B |
| Year End 30 September 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | |
| Total Assets | 13.5B | 15.84B | 34.96B | 48.16B | 48.07B |
| Total Liabilities | 6.09B | 7.67B | 26.66B | 30.86B | 30.13B |
| Total Equity | 7.41B | 8.17B | 8.29B | 17.3B | 17.94B |
| Year End 30 September 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | |
| Operating | 4.76B | 5.29B | 5.1B | 4.23B | 2.77B |
| Investing | -901M | -2.01B | -11.76B | -8.96B | -1.34B |
| Financing | -3.86B | -3.18B | 6.59B | 5.27B | -1.52B |
| Market Cap | 25.98B |
| Price to Earnings Ratio | 48.76 |
| Price to Sales Ratio | 9.11 |
| Price to Cash Ratio | 312.62 |
| Price to Book Ratio | 13.73 |
| Dividend Yield | 2.35% |
| Shares Outstanding | 2.1B |
| Average Volume (1 week) | 98.31k |
| Average Volume (1 Month) | 86.11k |
| 52 Week Change | 11.45% |
| 52 Week High | 14.3396 |
| 52 Week Low | 10.69 |
| Spread (Intraday) | 1.49 (11.78%) |
| Company Name | Coloplast AS (PK) |
| Address |
holtedam 1-3 humlebaek DK-3050 |
| Website | https://www.coloplast.com |
| Industry | health care diversified (H) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
